Method for NK cell transduction
AssigneeMiltenyi Biotec GmbH
InventorsRafijul Bari, Markus Granzin, Wing Leung, Nina Moker, Volker Huppert
Life of this patent
Estimating the term…
Loading patent…
AssigneeMiltenyi Biotec GmbH
InventorsRafijul Bari, Markus Granzin, Wing Leung, Nina Moker, Volker Huppert
Estimating the term…
The present invention discloses an in-vitro method for transferring biological material into activated NK cells with a pseudotyped retroviral vector particle or a virus-like particle thereof, comprising the steps a) activation of NK cells, and b) addition of said pseudotyped retroviral vector particle or virus-like particle thereof to said activated NK cells, wherein said pseudotyped retroviral vector particle or virus-like particle thereof comprises a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein that is able of binding to and fusing with a hematopoietic cell membrane, thereby transferring biological material into said activated NK cells. Preferentially, the activating of NK cells is performed by the addition of a IL-1 family cytokine to the NK cells.
A method for transducing human NK cells with a nucleic acid, the method comprising:
A method for improving efficiency of transducing a nucleic acid into human natural killer (NK) cells;
Dependencies are inferred from the claim text.